The new guidelines describe the features of chronic pulmonary aspergillosis (CPA) and provide comprehensive treatment recommendations.
Researchers designed a case-control study using de-identified commercial health claim information in the United States from January 1, 2007, to December 31, 2009.
Treatment was tested in critically ill patients with ICU-acquired sepsis, multiple Candida colonization, and multiple organ failure.
Flu may represent a novel host risk factor for this invasive fungal infection.
The updated guidelines focus on the diagnosis and treatment of the major forms of aspergillosis: allergic, chronic and invasive, the latter which kills 40% to 80% of those with widespread infection.
Drs Tapper and Crum-Cianflone discuss aspergillosis, an emerging complication of severe influenza infections.
Rapid identification of Candida auris is crucial in order to implement appropriate precautions and avoid transmission to other patients.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Generic HIV Medicines: Boon or Bust?
- Insulin-Treated Diabetes Reduces Dysglycemia-Related Mortality in Sepsis
- It Costs $2.2 Billion a Year to Treat Antibiotic Resistance
- Tricyclic Antidepressants May Reduce Cirrhosis Risk in Hepatitis C
- Pregnancy May Be Independently Associated With Prolonged Detection of Zika Virus RNA
- Clostridium difficile Infection in the Intensive Care Setting
- Combating Medically Important Antibiotic Use in Food-Producing Animals
- Religious Exemptions vs Mandatory Vaccinations: An Expert Perspective
- 2018 Vaccination Schedule: Adults
- Fingerstick Point-of-Care Test Allows for Single-Visit HCV Diagnoses
- Glecaprevir/Pibrentasvir Highly Efficacious for HCV/HIV Coinfection
- Fluoroquinolone Use May Increase Risk for Aortic Aneurysm and Dissection
- Reduced Risk of Hepatocellular Carcinoma in DAA-Treated HCV Infection
- Paracetamol Overuse During Cold and Flu Season
- C difficile Risk Higher With Stoma Reversal vs Colectomy